HCM: Utang kumulatif perusahaan HUTCHMED

Stable cash flow from Chinese sales and licenses ensures the resilience of HUTCHMED (HCM). The volume of borrowed funds illustrates the current debt load, where 0.08 determines the current value of the metric. HUTCHMED (HCM) is scaling the expansion of fruquintinib in the US and EU, while simultaneously developing global partnerships with pharma behemoths to conduct international clinical trials.

HCM: Gunggung utang perusahaan HUTCHMED Ltd 04.07.2022 - 30.10.2026

HUTCHMED (HCM) - rincian metrik lan laporan keuangan

- rega saham lan target rega konsensus:

Kurs saham HUTCHMED Corp|HCM - Prakiraan konsensus analis

- informasi kapitalisasi pasar:

Nilai pasar HUTCHMED Ltd|HCM - Nilai Total Perusahaan

- data nilai buku modal saham:

Nilai Akuntansi Saham HUTCHMED|HCM - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku hutch-med.com|HCM - Aset Agregat Perusahaan

- indikator beban kredit lan likuiditas emiten:

Utang marang Ekuitas HUTCHMED (China) Limited|HCM - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Hutchison MediPharma|HCM - Utang perusahaan|Utang-utang marang nilai buku HUTCHMED Ltd|HCM - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan HUTCHMED|Indikator likuiditas cepet hutch-med.com

- informasi bathi lan kelipatan valuasi:

HCM - Bathi resik perusahaan

Analisis fundamental perusahaan:HCM - HUTCHMED Corp

When assessing the resilience of HUTCHMED (China) Limited (HCM), investors must consider the cost of expansion into the US oncology sector amid pressure from global pharma behemoths. By analyzing the debt trend chart, we measure the total volume of borrowed funds, which determines the issuer's degree of financial dependence and the risk of overpaying on interest, directly impacting the company's free capital preservation.

Pesaing HUTCHMED (China) Limited